Unfortunately, both PDL1 and TMB are limited by issues of disharmony between assays, variable relevance across cancer types, and poor specificity (with responses still observed when the assay is deemed ‘negative’ and vice versa) [7, 8]. This evidence concerns the gene CD274 and cancer.